Xtandi Cost Dropped on MedsEngage
The Xtandi cost (enzalutamide) has been a topic of much debate in recent years. The drug, which is used to treat prostate cancer, has been found to be effective in prolonging the lives of patients with the disease. However, the high Xtandi cost has caused many to question its affordability. In 2016, the Xtandi cost was $129,000 for a year’s worth of treatment. This cost has causedmany insurance companies to refuse to cover the drug, leaving patients to pay for it out-of-pocket. The high price of Xtandi has also led to patients rationing their doses of the drug, which can be dangerous. There are a number of factors that contribute to the high cost of Xtandi. First, the drug is patented and the manufacturer, Astellas, has a monopoly on its production. Second, Xtandi is a new drug and, as such, its price is not yet regulated by the government. Finally, the cost of clinical trials and marketing the drug also contribute to its high price.
